Sartorius stock: Third-quarter results due October 22, 2026 for Sartorius stock

Published on 10/19/2026 at 16:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half 2026 revenue rose 2.47 percent to EUR 1.81 billion. Sartorius stock sits at EUR 262.85 on October 19, 2026, up 0.71 percent versus Xetra close.

Upcoming reporting date

Sartorius has scheduled its nine-month 2026 results for October 22, 2026.
First-half 2026 revenue rose 2.47 percent to EUR 1.81 billion.
Sartorius stock costs EUR 262.85 at Lang & Schwarz on October 19, 2026 at 3:41 p.m. CEST, 0.71 percent above the Xetra close of October 16, 2026.
Market capitalization was EUR 16.2 billion and P/E was 92.72 on October 19, 2026.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius has scheduled its nine-month 2026 results for October 22, 2026, according to its Sartorius investor-relations calendar. At Lang & Schwarz, the stock was trading at EUR 262.85 on October 19, 2026 at 3:41 p.m. CEST, up 0.71 percent versus the Xetra close of October 16, 2026 at EUR 261.00.

First-half revenue rose 2.47 percent

Sartorius generated EUR 1.81 billion in revenue during the first half of 2026, compared with EUR 1.77 billion in the prior-year period. That represents growth of 2.47 percent on a reported basis, according to FNE. Underlying EBITDA reached EUR 547.8 million, producing a 30.3 percent margin versus 29.8 percent a year earlier. The company also confirmed its 2026 outlook for constant-currency revenue growth of 5 to 9 percent and an underlying EBITDA margin slightly above 30 percent.

Stock stays below its yearly high

The October 19, 2026 52-week range extends from EUR 198.50 to EUR 271.90. At EUR 262.85, the stock stands 3.33 percent below the high and 32.42 percent above the low. The session quote also showed a day range from EUR 258.50 to EUR 265.80, while volume was 24,298 shares against an average of 100,797 shares.

Valuation meets an approaching date

Sartorius had a market capitalization of EUR 16.2 billion on October 19, 2026, with a P/E ratio of 92.72. The scheduled October 22 results are the next dated event for the stock. UBS had maintained a Buy rating and a EUR 300.00 target in a note dated October 14, 2026, according to finanzen.ch.

Comparison with peers

Sartorius (Xetra, EUR): plus 0.71 percent, P/E 92.72, market capitalization EUR 16.2 billion.

Thermo Fisher Scientific (NYSE, USD): minus 0.54 percent, P/E 36.86, market capitalization USD 253.7 billion.

Danaher (NYSE, USD): minus 1.07 percent, P/E 40.13, market capitalization USD 159.3 billion.

Price and results remain linked

The upcoming results will give investors a fresh basis for judging whether the first-half margin improvement can continue. The current euro quote remains 0.71 percent above the Xetra close of October 16, 2026.

The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.